The significance of the triglyceride/high-density lipoprotein cholesterol index as a predictor of major cardiovascular events
Abstract
Aim. To study the influence of the TG/HDL-C index on the development of major cardiovascular events in patients with coronary artery disease.
Materials and methods. The study included 221 patients with a diagnosis of coronary artery disease, progressive angina pectoris, hospitalized in the department of coronary heart disease and dyslipidemia. All patients were determined biochemical parameters and imaging markers.
Results. When comparing patients with and without metabolic syndrome, the latter had a higher TG/HDL-C index (p<0.001), as well as CVD (p<0.001). In addition, a 3-year follow-up showed that an increase in TG/HDL-C above a certain point (Yuden index 5.1) with a statistically significant result led to a more frequent development of MACE (p<0.001), revascularization (p<0.05). Based on the results of the study, a multiple logistic regression model was built using 4 significant variables - EFT, Age, Lp(a) and TG/HDL-C.
Conclusion. The triglycerides/high-density lipoprotein cholesterol index can serve as an additional criterion in the selection of lipid-lowering therapy to reduce the residual risk, with an increase in which the addition of fenofibrate should be considered.
About the Authors
List of references
Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118(4):547–563. https://www.ahajournals.org/ doi/10.1161/CIRCRESAHA.115.306249.
Ginsberg HN, Packard CJ, Chapman MJ, Bore´n J, Aguilar-Salinas CA, Averna M, Ference BA, Gaudet D, Hegele RA, Kersten S, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791–4806. https://doi.org/10.1093/ eurheartj/ehab551.
Nahmias A, Stahel P, Xiao C, Lewis GF. Glycemia and atherosclerotic cardiovascular disease: exploring the gap between risk marker and risk factor. Front Cardiovasc Med. 2020;7:100. https://doi.org/10.3389/ fcvm.2020.00100.
Gaziano JM, Hennekens CH, O’Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high density lipoprotein, and risk of myocardial infarction. Circulation. 1997;96(8):2520–2525. https://doi.org/10.116 1/01.CIR.96.8.2520.
Yuge H, Okada H, Hamaguchi M, et al. Triglycerides/HDL cholesterol ratio and type 2 diabetes incidence: Panasonic Cohort Study 10. Cardiovasc Diabetol. 2023;22:308. https://doi.org/10.1186/s12933-023-02046-5.
Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglycerides concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97(11):1029–1036. https://doi.org/10.1161/01.CIR.97.11.1029.
Hanak V, Munoz J, Teague J, Stanley A, Bittner V. Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype. Am J Cardiol. 2004;94(2):219–222. https://doi.org/10.1016/j.amjcard.2004.03.032.
Eshpulatov AS. Assessment of the association between the type of dyslipidemia and genes of the lipid transport system with coronary atherosclerosis in patients with unstable angina [PhD dissertation]. Tashkent; 2023. (Specialty: 14.00.06 – Cardiology). In Russian: Эшпулатов Азизбек Сағдуллаевич. «Ностабил стенокардияси бор беморларда коронар атеросклерозни дислипидемия тури ва ли- пидтранпорти системани генлари билан боғлиқлигини баҳолаш», 14.00.06-Кардиология (тиббиёт фанлари), фалсафа доктори (РhD) диссертацияси, Тошкент, 2023.
Kukharchuk VV, Ezhov MV, Sergienko IV, Murataliev TM, Myrzakhmetova GSh, Sudzhaeva OA, Shek AB, Azizov VA. Clinical guidelines of the Eurasian Association of Cardiologists (EAC) / National Society for the Study of Atherosclerosis (NSSA) on the diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis (2020). Eurasian Cardiol J. 2020;(2):6–29. https://doi.org/10.38109/2225-1685-2020-2-6-29. In Russian: Кухарчук В.В., М. В. Ежов, И. В. Серги- енко, Т. М. Мураталиев, Г.Ш. Мырзахметова, О.А. Суджаева, А.Б. Шек, В.А. Азизов. Клинические рекомендации Евразийской ассоциации кардиологов (ЕАК)/ Национального общества по изучению атеросклероза (НОА) по диагностике и коррекции нарушений липидного обмена с целью профи- лактики и лечения атеросклероза (2020). Евразийский кардиологический журнал. 2020;(2):6-29, https://doi.org/10.38109/2225-1685-2020-2-6-29.
Copyright (c) 2025 А.Р. Ким, Р.Б. Алиева, А.Б. Шек (Автор)
This work is licensed under a Creative Commons Attribution 4.0 International License.